JP2022534966A5 - - Google Patents

Info

Publication number
JP2022534966A5
JP2022534966A5 JP2021570756A JP2021570756A JP2022534966A5 JP 2022534966 A5 JP2022534966 A5 JP 2022534966A5 JP 2021570756 A JP2021570756 A JP 2021570756A JP 2021570756 A JP2021570756 A JP 2021570756A JP 2022534966 A5 JP2022534966 A5 JP 2022534966A5
Authority
JP
Japan
Application number
JP2021570756A
Other languages
Japanese (ja)
Other versions
JPWO2020243448A5 (https=
JP2022534966A (ja
JP7669291B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/035148 external-priority patent/WO2020243448A1/en
Publication of JP2022534966A publication Critical patent/JP2022534966A/ja
Publication of JPWO2020243448A5 publication Critical patent/JPWO2020243448A5/ja
Publication of JP2022534966A5 publication Critical patent/JP2022534966A5/ja
Priority to JP2025067310A priority Critical patent/JP2025118664A/ja
Application granted granted Critical
Publication of JP7669291B2 publication Critical patent/JP7669291B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021570756A 2019-05-30 2020-05-29 Actrii結合性タンパク質及びその使用 Active JP7669291B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025067310A JP2025118664A (ja) 2019-05-30 2025-04-16 Actrii結合性タンパク質及びその使用

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962854625P 2019-05-30 2019-05-30
US62/854,625 2019-05-30
PCT/US2020/035148 WO2020243448A1 (en) 2019-05-30 2020-05-29 Actrii-binding proteins and uses thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025067310A Division JP2025118664A (ja) 2019-05-30 2025-04-16 Actrii結合性タンパク質及びその使用

Publications (4)

Publication Number Publication Date
JP2022534966A JP2022534966A (ja) 2022-08-04
JPWO2020243448A5 JPWO2020243448A5 (https=) 2023-06-06
JP2022534966A5 true JP2022534966A5 (https=) 2023-06-06
JP7669291B2 JP7669291B2 (ja) 2025-04-28

Family

ID=73553540

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021570756A Active JP7669291B2 (ja) 2019-05-30 2020-05-29 Actrii結合性タンパク質及びその使用
JP2025067310A Pending JP2025118664A (ja) 2019-05-30 2025-04-16 Actrii結合性タンパク質及びその使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025067310A Pending JP2025118664A (ja) 2019-05-30 2025-04-16 Actrii結合性タンパク質及びその使用

Country Status (8)

Country Link
US (1) US12545736B2 (https=)
EP (1) EP3976630A4 (https=)
JP (2) JP7669291B2 (https=)
KR (1) KR20220029563A (https=)
CN (1) CN114127087A (https=)
AU (1) AU2020284038A1 (https=)
CA (1) CA3142149A1 (https=)
WO (1) WO2020243448A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof
JP2024511315A (ja) * 2021-03-10 2024-03-13 アクセルロン ファーマ インコーポレイテッド Actrii-alk4アンタゴニスト及び心不全の治療方法
US20250064952A1 (en) * 2021-03-10 2025-02-27 Acceleron Pharma Inc. Actrii-alk4 antagonists and methods of treating heart failure
JP2024532345A (ja) * 2021-09-03 2024-09-05 ラエクナ セラピューティクス シャンハイ カンパニー リミテッド 抗acvr2a抗体及びその使用
AU2024317572A1 (en) 2023-07-31 2026-03-12 Sixpeaks Bio Ag Antibody conjugates and fusion proteins
WO2025026353A1 (en) * 2023-08-01 2025-02-06 Laekna Therapeutics Shanghai Co., Ltd. Anti-acvr2b antibodies and uses thereof
WO2025068454A1 (en) * 2023-09-28 2025-04-03 Sixpeaks Bio Ag Antibodies targeting actriia and actriib
CN121344183B (zh) * 2025-12-18 2026-03-27 成都医学院 检测ACVR2b的试剂在制备慢性肾脏病血管钙化诊断试剂盒中的用途

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CL2007002567A1 (es) 2006-09-08 2008-02-01 Amgen Inc Proteinas aisladas de enlace a activina a humana.
JP5766179B2 (ja) 2009-04-27 2015-08-19 ノバルティス アーゲー 筋肉増殖を増加させるための組成物および方法
US8765385B2 (en) 2011-10-27 2014-07-01 Ravindra Kumar Method of detection of neutralizing anti-actriib antibodies
GR1007832B (el) 2011-11-21 2013-02-14 Ιδρυμα Ιατροβιολογικων Ερευνων Ακαδημιας Αθηνων, Αδρανοποιητες της ακτιβινης και χρηση τους για την θεραπεια ασθενειων που σχετιζονται με παρεκκλινουσα ενεργοποιηση της "αμυντικης αποκρισης του ξενιστη"
JP2015525230A (ja) 2012-06-11 2015-09-03 アムジエン・インコーポレーテツド デュアル受容体アンタゴニスト性抗原結合タンパク質およびその使用
WO2014172448A2 (en) * 2013-04-17 2014-10-23 Anaptysbio, Inc. Antibodies directed against activin receptor type ii (actrii)
TW201920262A (zh) 2013-07-30 2019-06-01 美商再生元醫藥公司 抗活化素a之抗體及其用途
PT3286206T (pt) 2015-04-22 2021-04-01 Biogen Ma Inc Novas proteínas híbridas bloqueadoras de ligando actriib para tratar doenças de desgaste muscular
AU2017222526A1 (en) 2016-02-22 2018-08-23 Acceleron Pharma Inc. ActRII antagonists for use in increasing immune activity
JP6987072B2 (ja) * 2016-03-10 2021-12-22 アクセレロン ファーマ インコーポレーテッド アクチビン2型受容体結合タンパク質及びその使用
FI3600415T3 (fi) 2017-03-24 2025-12-05 Novartis Ag Aktiviinireseptorin tyypin ii reseptorin vastainen vasta-aine käytettäväksi sydämen vajaatoiminnan hoidossa
AU2020284038A1 (en) 2019-05-30 2021-12-02 Acceleron Pharma Inc. ActRII-binding proteins and uses thereof

Similar Documents

Publication Publication Date Title
BR112023005462A2 (https=)
BR112023012656A2 (https=)
BR112021014123A2 (https=)
JP2022534966A5 (https=)
BR112023009656A2 (https=)
BR112022009896A2 (https=)
BR112021017747A2 (https=)
BR112022024743A2 (https=)
BR112022026905A2 (https=)
BR112023011738A2 (https=)
BR112023004146A2 (https=)
BR112023006729A2 (https=)
BR102021018859A2 (https=)
BR102021015500A2 (https=)
BR112023016292A2 (https=)
BR112023011539A2 (https=)
BR112023011610A2 (https=)
BR112023008976A2 (https=)
BR102021020147A2 (https=)
BR102021018926A2 (https=)
BR102021018167A2 (https=)
BR102021017576A2 (https=)
BR102021016837A2 (https=)
BR102021016551A2 (https=)
BR102021016375A2 (https=)